SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo. 1993

A Bachy, and M Héaulme, and A Giudice, and J C Michaud, and I A Lefevre, and J Souilhac, and L Manara, and M B Emerit, and H Gozlan, and M Hamon
Sanofi Recherche, Toulouse, France.

SR 57227A (4-amino-(6-chloro-2-pyridyl)-1 piperidine hydrochloride) is a novel compound with high affinity and selectivity for the 5-HT3 receptor. The compound had affinities (IC50) varying between 2.8 and 250 nM for 5-HT3 receptor binding sites in rat cortical membranes and on whole NG 108-15 cells or their membranes in vitro, assayed under various conditions with [3H]S-zacopride or [3H]granisetron as radioligand. Like reference 5-HT3 receptor agonists, SR 57227A stimulated the uptake of [14C]guanidinium into NG 108-15 cells in the presence of substance P (EC50 = 208 +/- 16 nM) and contracted the isolated guinea-pig ileum (EC50 = 11.2 +/- 1.1 microM), effects that were antagonised by the 5-HT3 receptor antagonist tropisetron. The agonist effect of SR 57227A was also observed in vivo, as the compound elicited the Bezold-Jarisch reflex in anesthetised rats (ED50 = 8.3 micrograms/kg i.v.), an effect that was blocked by tropisetron and R,S-zacopride, but not by methysergide. When injected unilaterally into the mouse striatum, SR 57227A, like 2-methyl-5-HT, elicited contralateral turning behaviour which was antagonised by ondansetron. Furthermore, microiontophoretic application of SR 57227A markedly inhibited the firing rate of rat cortical neurones, an effect antagonised by tropisetron. Finally, in contrast to reference 5-HT3 agonists, SR 57227A bound to 5-HT3 receptors on mouse cortical membranes after systemic administration (ED50 = 0.39 mg/kg i.p. and 0.85 mg/kg p.o.). These results suggest that SR 57227A is a potent agonist at peripheral and central 5-HT3 receptors, both in vitro and in vivo. In view of the dearth of 5-HT3 receptor agonists which are capable of crossing the blood-brain barrier, SR 57227A may be useful in the characterisation of the neuropharmacological effects produced by the stimulation of these receptors.

UI MeSH Term Description Entries
D007082 Ileum The distal and narrowest portion of the SMALL INTESTINE, between the JEJUNUM and the ILEOCECAL VALVE of the LARGE INTESTINE.
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008297 Male Males
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D010880 Piperidines A family of hexahydropyridines.
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D001812 Blood-Brain Barrier Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue. Brain-Blood Barrier,Hemato-Encephalic Barrier,Barrier, Blood-Brain,Barrier, Brain-Blood,Barrier, Hemato-Encephalic,Barriers, Blood-Brain,Barriers, Brain-Blood,Barriers, Hemato-Encephalic,Blood Brain Barrier,Blood-Brain Barriers,Brain Blood Barrier,Brain-Blood Barriers,Hemato Encephalic Barrier,Hemato-Encephalic Barriers
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell

Related Publications

A Bachy, and M Héaulme, and A Giudice, and J C Michaud, and I A Lefevre, and J Souilhac, and L Manara, and M B Emerit, and H Gozlan, and M Hamon
January 2019, Biochemical and biophysical research communications,
A Bachy, and M Héaulme, and A Giudice, and J C Michaud, and I A Lefevre, and J Souilhac, and L Manara, and M B Emerit, and H Gozlan, and M Hamon
January 1995, Journal of neural transmission. General section,
A Bachy, and M Héaulme, and A Giudice, and J C Michaud, and I A Lefevre, and J Souilhac, and L Manara, and M B Emerit, and H Gozlan, and M Hamon
October 1992, Journal of autonomic pharmacology,
A Bachy, and M Héaulme, and A Giudice, and J C Michaud, and I A Lefevre, and J Souilhac, and L Manara, and M B Emerit, and H Gozlan, and M Hamon
February 1995, British journal of pharmacology,
A Bachy, and M Héaulme, and A Giudice, and J C Michaud, and I A Lefevre, and J Souilhac, and L Manara, and M B Emerit, and H Gozlan, and M Hamon
August 1990, Brain research,
A Bachy, and M Héaulme, and A Giudice, and J C Michaud, and I A Lefevre, and J Souilhac, and L Manara, and M B Emerit, and H Gozlan, and M Hamon
May 1999, Journal of medicinal chemistry,
A Bachy, and M Héaulme, and A Giudice, and J C Michaud, and I A Lefevre, and J Souilhac, and L Manara, and M B Emerit, and H Gozlan, and M Hamon
July 1998, Synapse (New York, N.Y.),
A Bachy, and M Héaulme, and A Giudice, and J C Michaud, and I A Lefevre, and J Souilhac, and L Manara, and M B Emerit, and H Gozlan, and M Hamon
April 1988, European journal of pharmacology,
A Bachy, and M Héaulme, and A Giudice, and J C Michaud, and I A Lefevre, and J Souilhac, and L Manara, and M B Emerit, and H Gozlan, and M Hamon
October 2002, European journal of pharmacology,
A Bachy, and M Héaulme, and A Giudice, and J C Michaud, and I A Lefevre, and J Souilhac, and L Manara, and M B Emerit, and H Gozlan, and M Hamon
November 2016, ACS chemical neuroscience,
Copied contents to your clipboard!